What are the Implications of the Approval of Aduhelm (Aducanumab) to the US Healthcare System?
Manage episode 446201003 series 3609642
In this episode we continue our discussion of the implications of the approval of the Alzheimer’s drug Aduhelm (generic name Aducanumab). Our guest this week is Professor Nicholas Bagley. Bagley is a professor of law at the University of Michigan Law School and a contributing writer to the Atlantic. Recently he wrote an article titled “The Drug that Could Break American Health Care” that discusses some of the broader (unintended) consequences of the approval of Aducanumab. In this episode we discuss some of the broader cost implications of the new drug.
PRODUCER’S NOTE: Since the recording of this interview, Medicare officials have announced the largest ever dollar-amount rate hike for Part B coverage citing the need to build contingency reserves to potentially cover the Alzheimer’s drug, Aduhelm. Professor Bagley discusses the concern of the cost of Aduhelm to the US Healthcare System in this Minding Memory episode.
The transcript for this episode can be found here.
Related Links:
- CAPRA Website: http://capra.med.umich.edu/
- Atlantic Article – The Drug that Could Break American Healthcare by Nicholas Bagley & Rachel Sachs: https://www.theatlantic.com/ideas/archive/2021/06/aduhelm-drug-alzheimers-cost-medicare/619169/
You can subscribe to Minding Memory on Apple Podcasts, Spotify, Google Podcasts or wherever you listen to podcasts.
Hosted on Acast. See acast.com/privacy for more information.
40 episodes